DrugPatentWatch Database Preview
Mechanism of Action: Cytochrome P450 3A4 Inhibitors
» See Plans and Pricing
Drugs with Mechanism of Action: Cytochrome P450 3A4 Inhibitors
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | ZORTRESS | everolimus | TABLET;ORAL | 021560-004 | Aug 10, 2018 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Novartis | ZORTRESS | everolimus | TABLET;ORAL | 021560-001 | Apr 20, 2010 | AB | RX | Yes | No | Start Trial | Start Trial | Start Trial | |||
| Novartis | ZORTRESS | everolimus | TABLET;ORAL | 021560-002 | Apr 20, 2010 | AB | RX | Yes | No | Start Trial | Start Trial | Start Trial | |||
| Novartis | ZORTRESS | everolimus | TABLET;ORAL | 021560-003 | Apr 20, 2010 | AB | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | |||
| Almirall | XOLEGEL | ketoconazole | GEL;TOPICAL | 021946-001 | Jul 28, 2006 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-001 | Oct 19, 2009 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-001 | Oct 19, 2009 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
